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Tailored biological retention and efficient clearance 
of pegylated ultra-small MnO nanoparticles as 
positive MRI contrast agents for molecular imaging  
P. Chevalliera, A. Walterb, A. Garofalob, I. Vekslera, J. Lagueuxc, S. Bégin-Colinb, D. 
Felder-Fleschb, M.-A. Fortina* 
A majority of MRI procedures requiring intravascular injections of contrast agents are performed with 
paramagnetic chelates. Such products induce vascular signal enhancement and they are rapidly excreted 
by the kidneys. Unfortunately, each chelate is made of only one paramagnetic ion, which, taken 
individually, has a limited impact on the MRI signal. In fact, the detection of molecular events in the 
nanomolar range using T1-weighted MRI sequences requires the design of ultra-small particles 
containing hundreds of paramagnetic ions per contrast agent unit. Ultra-small nanoparticles of 
manganese oxide (MnO, 6 – 8 nm diam.) have been developed and proposed as an efficient and at least 
1000x more sensitive “positive” MRI contrast agent. However no evidence was found until now, that an 
adequate surface treatment of these particles could maintain their strong blood signal enhancement, 
while allowing their rapid and efficient excretion by the kidneys or by the hepatobiliairy pathway. 
Indeed, the sequestration of MnO particles by the reticuloendothelial system, followed by strong uptake 
in the liver and in the spleen could potentially lead to Mn2+-induced toxicity effects. For ultra-small MnO 
particles to be applied in the clinics, it is necessary to develop coatings that also enable their efficient 
excretion within hours.  This study demonstrates for the first time the possibility to use MnO particles as 
T1 vascular contrast agents, while enabling the excretion of >70% of all the Mn injected dose after 48h.  
For this, small, biocompatible and highly hydrophilic pegylated bis-phosphonate dendrons (PDn) were 
grafted on MnO particles to confer colloidal stability, relaxometric performance, and fast excretion 
capacity. The chemical and colloidal stability of MnO@PDn particles were confirmed by XPS, FTIR and 
DLS. The relaxometric performance of MnO@PDns as “positive” MRI contrast agents was assessed (r1 
= 4.4mM-1s-1, r2/r1 = 8.6; 1.41 T and 37
◦C). Mice were injected at 1.21 µg Mn/kg (22 µmol Mn/kg), and 
scanned in MRI up to 48 h. The concentration of Mn in key organs was precisely measured by neutron 
activation analysis and confirmed, with MRI, the possibility to avoid RES nanoparticle sequestration 
through the use of phosphonate dendrons. Due to the fast kidney and hepatobiliairy clearance of MnO 
particles conferred by PDns, MnO nanoparticles can now be considered for promising applications in T1-
weighted MRI applications requiring less toxic although highly sensitive “positive” molecular contrast 
agents.  
 
 
 
1 Introduction 
Magnetic resonance imaging (MRI), one of the most widely 
available medical imaging modalities, allows high-resolution, whole-
body anatomical studies without the use of ionizing radiation. MRI 
is particularly useful in modern medicine, to differentiate diseased 
tissues from their surroundings. For this, it is often necessary to 
inject contrast agents (CAs) which have the capacity to influence the 
signal from 1H protons. Hydrogen protons contained in water 
molecules either complexed with, or located in the close vicinity of 
paramagnetic and superparamagnetic CAs, relax faster. To induce 
such effects, metallic elements such as iron, manganese and 
gadolinium are the more commonly used, either in the form of 
molecules or nanoparticles. 
There is a need in molecular medicine, to develop imaging probes 
that could detect subtle molecular targets at an early stage of 
different diseases.1 However, molecular imaging with MRI is still 
lagging behind in terms of detection sensitivity, compared with 
nuclear imaging methods such as positron emission tomography 
(PET). In addition to molecular imaging, new biomedical procedures 
also require cells to be labeled before their injection in vivo, 
followed by their detection at time points.2 By bringing hundreds of 
paramagnetic ions into single CA units, it is possible to considerably 
enhance the capacity of MRI to detect single molecular targets, or 
small clusters of locally injected cells.  
The development of molecular and cellular medicine has led to the 
recent development of a new generation of “positive” MRI CAs 
based on ultra-small Gd, Dy or Mn-containing nanoparticles of 
diameters in the range 2 - 10 nm.1, 3-13 By opposition to iron oxide 
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nanoparticles, ultra-small nanoparticles made of MnO, Gd2O3, 
GdPO4 and NaGdF4 preferentially decrease the longitudinal 
relaxation time of hydrogen in water molecules, inducing thereby a 
strong MR signal enhancement in T1-weighted MRI. With very high 
fractions of surface atoms, ultra-small particles of gadolinium oxide 
(Gd2O3), gadolinium fluoride (GdF3, NaGdF4) and manganese oxide 
(MnO) have emerged as particularly promising candidates for 
“positively contrasted” molecular and cellular MRI applications.4-10, 
12, 14-17 In fact, small nanoparticles showing high atomic surface 
ratios induce stronger positive contrast enhancement in MRI.18 
These particles, stable in saline suspensions, are coated with 
biocompatible and hydrophilic molecules (e.g. PEG, D-glucoronic, 
dextran). In the recent years, concerns related to the occurrence of 
nephrogenic systemic fibrosis (NSF), a pathology now associated 
with the use of gadolinium in MRI, has led to FDA restrictions on 
the clinical use of this lanthanide element.19-23 Promising alternatives 
based on Mn-containing nanoparticles have been developed, to 
attenuate their toxicological risks.24-27  
Thermal decomposition has been one of the most widely used and 
reliable routes to produce relatively large nanoparticle synthesis 
batches of small and narrow particle size distributions.8, 11, 28 More 
recently, one-pot synthesis techniques have also been developed in 
high boiling point solvents, enabling the production of 1 - 3 nm 
diam. particles.4 After synthesis, the particles are covered by ligands 
or polymers, and suspended in water to measure their hydrodynamic 
size and properties as MRI contrast agents. For this, both the 
transverse and the longitudinal relaxation rates (1/T2, 1/T1) are 
measured, and plotted against Mn concentration values to calculate 
r2 and r1 (the “relaxivities”). High r1 values, and r2/r1 values as close 
as possible to 1 are necessary to demonstrate the potential of 
“positive” contrast agents for molecular MRI. The first of such 
studies with MnO particles, was performed by  Na et al. 8  PEG-
lipid-coated MnO nanoparticles (7 – 25 nm core diameter) were 
developed, and these studies revealed the strong dependence of the 
nanoparticle core surface on the longitudinal relaxivity. 
Unfortunately, very low longitudinal relaxivities were found (r1 = 
0.37 mM-1s-1 and r2/r1 = 4.7 for 7 nm-diameter MnO nanocrystals at 
3 T). The rather low relaxivities nonetheless were used to label and 
to track rat glioma cells in vivo, using T1-weighted imaging 
sequences.29 Then, hollow MnO particles with a ∼25 nm-thick 
porous silica shell were designed as high-stability cell tracking 
imaging probes.30 Compared with the latter, the longitudinal 
relaxivity of these particles appeared slightly increased (r1= 0.99 
mM-1s-1 at 11.7 T), allowing the tracking of mesenchymal stem cells 
over a period of at least 14 days. However, the longitudinal 
relaxivity of these suspensions was still four (4) to ten (10) times 
lower than that observed for common clinical CAs such as Gd-
DTPA and Gd-DOTA.31, 32 In fact, coating MnO particles with a 
layer of silica, considerably affect optimal water exchange between 
the matrix and the surface paramagnetic ions, which is a key 
mechanism guaranteeing the performance of “positive” MRI contrast 
agents.33 Although Mn2+ ions are paramagnetic, MnO nanoparticles 
in the range 5 – 10 nm, express an antiferromagnetic behaviour.34  
The most significant increase in relaxivity was reported for MnO 
particles synthesized with polyol techniques, (r1 = 7.75 at 1.5T, for 
PEG-coated MnO particles).4 However, the relaxometric ratio of 
these particles were close to that of Mn ions (r2/r1 ∼10), revealing the 
possible degradation of MnO cores upon complexation with 
carboxylic ligands. Indeed, aqueous Mn2+ solutions show relaxivities 
in the order of  r1 = 5.2 mM
-1s-1 and r2 = 61 mM
-1s-1 at 1.41 Tesla 
and 25oC.35 Hence, different coating strategies were recently adopted 
to provide enhanced colloidal stability, with possible improvement 
on the chemical stability of nanoparticles. 10, 18   
Unfortunately, no clear demonstration of enhanced chemical stability 
was performed after the coating of MnO particles with 
carboxymethyldextan and polyethylene sulfonate molecules. An 
optimal polymeric ligand that could prevent nanoparticle core 
degradation, while preserving relaxometric properties and colloidal 
stability is still to be developed. Although manganese is considered 
less toxic than gadolinium, amounts of Mn2+ ions are associated with 
the occurrence of manganism, a disease that takes symptoms close to 
that of Parkinson.36 In order for MnO nanoparticles to be considered 
as molecular and cellular CAs, the new coating must also prevent the 
leaching of Mn2+, and favor a strong and rapid excretion of the 
particles through the urinary and gastrointestinal tracts. Indeed, the 
transit of MnO particles in vivo must be limited to a few hours to 
minimize the potential toxicity risk to organs. Until now, no 
comprehensive study has been done to measure the biodistribution of 
MnO particles.  
One class of polymeric ligands could answer the stringent needs for 
high colloidal stability, optimal relaxometric capacities, and 
prevention of MnO core degradation: phosphonate dendrons. Indeed, 
dendron molecules made of short oligoethylene glycol chains have 
been recently developed, containing phosphonate groups that readily 
react with metal oxide surfaces.37-40 In particular, such molecules 
were successfully used to cover iron oxide nanoparticles. Upon 
reaction with the phosphonate moieties, the particles present a thin 
layer of iron phosphonate at their surface. In fact, surface 
phosphatisation/phosphonatisation has been widely used in a variety 
of industrial processes, to prevent the chemical degradation of 
oxidised metal surfaces. In this case, a similar strategy is applied at 
the nanoscale level to form a chemical phase that is more stable than 
the parent metal oxide. Moreover, the phosphonate dendron 
molecules also have a very singular capacity for being recognized 
and efficiently excreted by the renal and hepatobiliairy systems, as 
demonstrated in recent MRI studies performed after intravenous 
injections in the mouse model.37-40  The procedures evidenced a 
rapid and strong excretion of particles through the gastro-intestinal 
tract and through the kidneys.  
Not only the PEG chains confer a strong colloidal stability to the 
particles, it is also expected to generate a very stable phosphonatised 
coating at the surface of the transition metal oxide cores preventing 
magnetite Fe3O4 from oxidation and preserving the nanoparticles 
magnetic properties. Manganese phosphonate is chemically much 
more stable than manganese oxide and the stability of the metal 
complexes increases with increasing number of phosphonic acid 
groups.41 Therefore, coating ultra-small MnO particles with 
phosphonate dendrons represent a promising way to enhance their 
chemical and colloidal stability, to enhance their excretion 
efficiency, and to decrease their potential toxicity.  
In this study, a new poly(ethylene glycol)-bis-phosphonate dendron 
(PDn) of defined structure and composition, was efficiently grafted 
at the surface of MnO particles. Such dendron bears a phosphonate 
tweezer to ensure a stronger anchoring at the nanoparticle surface. 
The efficiency of ligand exchange on MnO particles as well as the 
strong involvement of phosphonate groups in the chelating process 
was confirmed by XPS and FTIR. The colloidal stability of the 
particles was investigated by DLS, and their relaxometric properties, 
quantified by 1H-NMR. Intravascular (i.v.) injections of MnO@PDn 
were performed under MRI using the mouse model. Finally, a 
biodistribution study was performed to quantify the diffusion, 
excretion and retention of Mn in organs after 24 and 48 h. 
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2 Experimental 
2.1 MnO nanoparticle synthesis 
MnO nanoparticles were synthesized by thermal decomposition.8, 11 
Typically, 2.0 g of Mn(NO3)2*xH2O (99.99%) and 6.8 g of sodium 
oleate were dissolved in a mixture of 160 mL ethanol, nanopure 
water and n-hexane (1:1:2 v/v), refluxed at 70°C for 29h. Thus-
formed Mn-oleate complex was decanted, washed with nanopure 
water twice and dried under vacuum for at least 24h. This complex 
was then dissolved in 40 mL of hexadecene and sonicated for 2h at 
40°C. The mixture was heated under argon flux (5°C /min) until 
282°C (kept for 3 min only). The nanoparticles suspension was 
cooled rapidly to 10°C and then sonicated, then washed using a 
repeated sequence of ethanol and acetone rinsing intercalated by 
centrifugation steps (1600g, 10°C, 20 min). Finally, 10 mL of 
cyclohexane was added which provided a clear suspension of 
MnO@oleate nanoparticles. 
2.2 Dendron synthesis and characterization 
A comprehensive description of the PEG-phosphonate dendron 
synthesis procedure is available in the supporting information.  
2.3 Dendron grafting on MnO nanoparticles 
The ligand exchange was performed by phase transfer process. 
For this, 10 mg of MnO@oleate nanoparticles were dispersed 
in hexane (1mg/mL), and added to an aqueous suspension of 
phosphonate dendrons (PDn, 10 mg in 10 mL ultrapure water 
adjusted to pH 3.5 with HCl). The two immiscible phases were 
magnetically stirred for one night to allow the grafting of PDns 
at the MnO surface occurring at the water-hexane interface.  
Ultrafiltration was used to separate MnO@PDn from ungrafted 
dendrons and from residual oleic acid.  For this, regenerated 
cellulose membranes were used (nominal molecular weight 
limit: 30kDa; Millipore). After 3 purification steps, the 
MnO@PDn suspension was collected and lyophilized overnight 
then preserved in a dry state until colloidal, relaxometric and 
MRI studies.  
2.4 Preparation of MnO@PDn nanoparticle suspensions for 
DLS, relaxometric and MRI studies 
Lyophilised MnO@PDn nanoparticles (70 mg) were suspended 
in 7 mL of nanopure water (18 MΩ⋅cm), vortexed 5 min, 
followed by a mild sonication step (15 min). Then, the particles 
were further dispersed using a sonication rod (60 MHz, 10 
min). Aggregates were eliminated by centrifugation (1000g, 10 
min). The resulting suspension was subsequently filtered at 
0.45 µm (cellulose acetate syringe filter, VWR Int. North 
America), then at 0.2 µm (polyethersulfone, VWR Int., North 
America). The hydrodynamic diameter of the particles was 
measured by DLS. The final nanoparticle suspension was 
adjusted to 154 mM NaCl (1 M NaCl). The amount of Mn in 
the 154 mM NaCl solution was measured by graphite furnace 
atomic absorption spectroscopy (GF-AAS; Perkin-Elmer 
Analyst 800). Prior to these measurements, the samples were 
digested in nitric acid (trace metal, Fisher) and hydrogen 
peroxide (H2O2, Sigma-Aldrich). 
2.5 Particle size analysis 
The MnO nanocore size distributions were assessed by 
transmission electron microscopy (TEM, 120 or 200 keV: 
JEOL-1230 and JEOL JEM-2100F, before and after 
dendronisation. In brief, the suspensions were diluted in 
methanol (1:10). Three (3) µL were deposited on carbon-coated 
copper grids (Canemco-Marivac, Lakefield, Canada) then dried 
before imaging. The ImageJ software particle size analysis tool 
was used to measure the distribution of the oxide cores. The 
hydrodynamic diameter of MnO@PDn in water and in 154 mM 
NaCl were confirmed by dynamic light scattering (DLS, 
Malvern Zetasizer 173°, t = 25◦C). The viscosity and refractive 
index of water was set to 0.8872 cp and the MnO refractive 
index of the particles was fixed to 2.160 (used to transform 
intensity in volume and number). The hydrodynamic diameter 
was calculated from the average of six measurements. 
2.6 Physico-chemical characterisation: FTIR and XPS 
Aqueous and methanol suspensions of MnO@PDn were deposited 
on a Si crystal then dried and analyzed by ATR-FTIR (Agilent Cary 
660 FTIR, Agilent Technologies, USA), equipped with a deuterated 
L-alanine doped triglycine sulfate (DLa-TGS) detector and a Ge 
coated KBr beam splitter. The particles as well as the dendron were 
also characterized by XPS (PHI 5600-ci spectrometer, Physical 
Electronics U.S.A., MN, U.S.A.). Samples of MnO@PDn particles 
were deposited and dried on silicon substrates previously cleaned by 
TL2 and TL1 solutions (TL2 solution, a mixture of ultrapure water, 
30% hydrogen peroxide (H2O2, Fluka, ON, Canada) and 
concentrated hydrochloric acid Fisher, Canada) (6:1:1), at 80°C for 
10 min and TL1 solution, a mixture of ultrapure water, 30% H2O2 
and 25% ammonia (Fisher, IL, USA) (5:1:1), at 80°C for 10 min). 
The wafers were thoroughly rinsed with ultrapure water and 
anhydrous ethanol, quickly dried under medical air. MnO@PDn 
particles deposited on these substrates were then analyzed by X-ray 
photoelectron spectroscopy (XPS) using a monochromatic aluminum 
X-ray source for survey spectra (0−1400 eV) at 200 W, while high 
resolution spectra of C1s, O1s, N1s and P2p were obtained by using 
a standard magnesium X-ray source (1253.6 eV), at 150 W. For 
neither analysis was applied charge neutralization. The detection was 
performed at 45° with respect to the surface normal and the analyzed 
area was 0.005 cm2. The spectrometer work function was adjusted to 
give 285.0 eV for the main C (1s) peak. Curve fittings for both the 
survey and the high resolution C (1s) peaks were determined by 
means of least squares minimization procedure employing Gaussian-
Lorentzian functions and a Shirley-type background. 
2.7 1H relaxometric measurements 
The stock solution of MnO@PDn particles in 154 mM of NaCl 
were diluted (to 5, 10, 15 and 25% v/v) and distributed in NMR 
tubes. Then, longitudinal and transverse relaxation times (T1 
and T2) were measured at 60 MHz (1.41 T) using a Bruker 
MiniSpec relaxometer. The temperature was set to 37°C for all 
measurements. Finally, the relaxation rates (1/T1 and 1/T2) were 
plotted against Mn concentration values (from GF-AAS), and 
relaxivities (r1 and r2) were calculated from the slope of the 
graphs. 
2.8 Colloidal stability assay 
MnO@PDn suspensions in water and in 154 mM NaCl, were 
left at room temperature and measured over time with DLS 
(24h, 48h, 7, 14, 21 days). 
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2.9 In vitro contrast media MRI studies 
The stock solution of MnO@PDn particles in 154 mM of NaCl 
were diluted (to 5, 10, 15 and 25% v/v) and distributed in 500 
µl-tubes immersed in water. The tubes were inserted in a 60-
mm RF coil and imaged at 25oC with a 1 T small-animal MRI 
system (M2M, Aspect Imaging, Netanya, Israel). T1-weighted 
2D spin-echo sequences were used, as follows: TE = 10.8ms; 
TR = 400ms, 700ms and 1000ms; fα=90°; FOV= 70 mm; 1.9 
mm slices with 0.1 mm gap; dwell time =16 µs, matrix: 200 X 
200; 3 exc. A series of T2-weighted 2D spin echo sequence was 
also performed (TE = 50, 75 ms and 100 ms; TR = 2500 ms; 
fα=90°; 1 exc.), that confirmed the weak performance of MnO 
particles as “negative” contrast agents. 
2.10 In vivo MRI and biodistribution studies 
Aliquots of the MnO@PDn suspensions in 154 mM NaCl were 
adjusted to a concentration of 4.4 ± 0.1 mM Mn. All animal 
experiments were conducted under the guidelines of Université 
Laval and CHUQ’s animal ethical committee. Four week-old balb/c 
female mice (Charles River, Montreal, Canada) were anaesthetised 
with isoflurane and placed on a dedicated bed inside a 3.5 cm-
diameter RF coil while their respiration was monitored. Animals 
were cannulated in the caudal tail vein (30G, winged needle), and 
connected to a catheter prewashed with heparin and connected to the 
contrast media syringe (280µm ID Intramedic™ Polyethylene 
Tubing PE-10, 60 cm, total volume: 60 µL). Prior to injections, the 
animals were scanned twice using a T1-weighted 2D spin echo 
sequence, with the following parameters: TE = 18.3ms; TR = 
800ms; fα=90°; FOV= 90 mm; 0.7 mm slices with 0.1 mm gap; 
dwell time =25 µs, matrix: 400 X 320; duration: 4min16s. At time 
t = 0, the animals (3) were injected with 100 µL of nanoparticle 
suspension (4.4 ± 0.1 mM Mn; total Mn injected = 0.44 µmol, or 
24.1 µg).  The same MR sequence was repeated for at least 120 
minutes. These animals were scanned again at t = 8, 24, 48 hours 
(static scans, 4.16 min each). A total of three (3) animals were 
injected for each nanoparticle product. For signal analysis, raw 
signal data were extracted, and regions of interest (ROIs), drawn 
over sections of the abdominal aorta, left kidney, bladder and gall 
bladder. The mean signal intensity was calculated using Image J 
software (version 1.44m; Wayne Rasband, National Institutes of 
Health, USA). Signal enhancement ratios were calculated as follows:  
 
Ratio 	




  Equation 1 
Finally, after 48 hours the mice were euthanatized by 
intracardiac exsanguination. A selection of organs were 
collected and weighted, prior to Mn quantification by neutron 
activation analysis (Slowpoke Laboratory, École Polytechnique 
de Montréal). To complete the 48h biodistribution data with an 
intermediate point, a group of mice (3) were injected and 
euthanatized at t = 24, and measured for Mn organ levels. 
 
3 Results and discussion 
3.1. Synthesis and particle size studies 
Ultra-small MnO particles, synthesized by thermal decomposition, 
are initially covered with oleate, a hydrophobic molecule. Then, 
oleate is removed upon reaction with PDns through a ligand 
exchange and phase transfer process. In the present study, highly 
water soluble and biocompatible bifunctional dendrons were used. A 
comprehensive schematic representation of the dendron synthesis is 
summarised in Schemes S1 and S2 (in the supporting information), 
as well as a detailed description of synthesis and characterisation at 
each step (Figures S1 – S4). The phosphonate dendron 13 obtained 
as a result of this synthesis chain is represented in Figure 1.a and 
Scheme S2. Compared to other dendrons previously reported in the 
literature, 13 features a bisphosphonic acid tweezer. This coupling 
agent was designed to allow a stronger and more efficient binding to 
NPs, compared to monophosphonate dendrons,37, 42, 43 and thus better 
long-term colloidal stability in physiological media.44-46 The dendron 
also features a hydrophilic PEGylated structure with carboxylic acid 
as terminal groups for nanoparticle functionalization. The 
bisphosphonate precursor 8 (Figure 1) was obtained starting from 
commercially available ethyl 3,5-dimethylbenzoate (see supporting 
information), and the coupling of the PEGylated dendron 4 (see ESI) 
with bisphosphonate 8 was obtained via a classical peptide-type 
coupling (Figure1 and ESI). The PEGylated dendron 12 was finally 
fully deprotected in one step in the presence of trimethylsilyl 
bromide to give COOH-functionalized bisphosphonic acid 13.  
The size of MnO cores was measured with TEM before (8.4  ± 0.8 
nm) and after ligand exchange (6.3 ± 0.7 nm) with PDns, as shown 
in Figure 1 (on at least 100 particles for each sample). The grafting 
mechanism had a significant impact on the mean diameter of the 
MnO oxide cores. This represents a mean volume decrease of 
57.8%. This diameter is attributed to the presence of a manganese 
hydroxide layer (∼ 1 nm thick) forming at the surface of the particles 
upon reaction with water, and prior to reaction with PDn. Indeed, 
Mn hydroxide is more susceptible to degrade under interactions with 
phosphonate groups, resulting in Mn2+ leaching during the ligand 
exchange process. After PDn reaction, traces of the crystal lattice of 
MnO cores were still visible at the center of MnO particles (Figure 
2a, white arrow, HRTEM 200 keV). The MnO crystal cores were 
unfortunately too small to allow the extraction of a clear electron 
diffraction pattern. The apparent thickness of the coating indicated 
the formation of a thick, P-containing (EDS data, Figure S5) 
inorganic layer at the interface between the MnO crystal and the 
PDns chains. At certain places in the TEM grid, a limited presence 
of a lower density P-containing phase (EDS confirmed) was 
identified, attributed to the presence of unreacted PDn (Figure 2b, 
dashed white arrow).  
After suspension of the particles in water and in saline, volume-
weighted hydrodynamic diameters of 13.4 ± 1.6 nm (34.5 nm in 
intensity) and 30.7 ± 2.3 (55.0 in intensity) were found, respectively 
(Figure 2.c,d). For the particles suspended in water, at day 0, the Z-
average was 24.8 ± 0.2 and the PDI value was 0.260 ± 0.005. After 
21 days, similar values were found (25.4 ± 0.3 and the PDI value 
was 0.262 ± 0.005). For the particles suspended in saline, at day 0, 
the Z-average was 41.8 ± 0.5 and the PDI value was 0.235 ± 0.008. 
After 21 days, similar values were found (41.4 ± 0.5 and the PDI 
value was 0.286 ± 0.004).  
Number-weighted data (Figure 2.e) indicated much lower 
hydrodynamic diameters, in agreement with the expected values for 
MnO@PDn (8.1 ± 1.7 nm and 20.4 ± 1.1 nm). Because PDns 
contain two phosphonate moieties, cross-reactions between two 
nanoparticles cannot be ruled-out. This possibly explains the limited 
presence of small aggregates suggested by the larger-than-expected 
hydrodynamic sizes diameters (volume-weighted data, Figure 2.b 
and d). Finally, the colloid was very sable in both saline and 
deionised water for at least 21 days, with larger hydrodynamic sizes 
in the saline solution (Figure 2.c,d,e). No sign of flocculation was 
found during the repeated DLS analysis. The zeta potential, 
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measured in 154 mM NaCl and at pH 6, was – 18.6 mV. This 
confirms the fact that strong electrostatic forces add up to the steric 
repulsion induced by the PEG chains, and confer a robust colloidal 
stability to the suspension.  
3.2. Physico-chemical surface analysis of MnO@PDn particles  
FTIR analysis was performed to assess the efficiency of ligand 
exchange (Figure 3). The intensity of the main peaks associated to 
MnO@oleate particles was strongly modified, in particular the CH 
vibration bands around 2922 and 2852 cm-1 as well as asymmetric 
(υas (CO2
-)) and symmetric (υs (CO2
-)) carboxylate stretching bands 
at 1553 cm-1 and 1429 cm-1. These bands present on the 
MnO@oleate spectrum were largely attenuated in the MnO@PDn 
spectrum, confirming the elimination of oleate, and the efficiency of 
ligand exchange. Upon PDn grafting, new bands appeared, 
characteristic of the chemical structure of PDn: 3097 cm-1 associated 
to the CH vibration in the aromatic ring; 1740 cm-1 associated to the 
C=O band of the carboxylic acid function; 1648 cm-1 associated to 
the C=O band of the amide link. The peak at 1097 cm-1 can be 
assigned mainly to the C-O vibration in the PEG structure and to a 
possible contribution from aromatic C-C bonds. This confirms the 
strong presence of PEG grafted at the MnO particles. 
The peaks in the range 1280 - 700 cm-1 are mainly associated to 
phosphonate bands (Figure 3.b). Phosphonate derivatives bands were 
difficult to precisely associate with given MnO-phosphonate 
chelation types. Indeed, each band can possibly refer to two or more 
vibration types. As an example, P=O and P-OH are susceptible to be 
strongly affected by their chemical environment. Others are affected 
by the pH (PO3
2-, PO2
-). Chemical links also affect the bands (either 
free, H or metallic links), leading to asymmetric and symmetric 
vibrations for a same group. It was nonetheless possible to ascribe 
the band at 1234 cm-1 to the P=O bond.38, 40, 47 The strong intensity 
decrease after complexation with MnO, as well as a splitting of this 
band at 1221 cm-1 suggest either its involvement in the chelation 
process or hydrogen bonding of P=O with the surface. Because each 
PDn contains a bisphophonate head, one P=O group can be involved 
in chelation and/or hydrogen bonding whereas the other one remains 
free. Therefore, the P=O band was not fully attenuated. Also, as 
indicated by the TEM results (Figure 2.b), the presence of a certain 
fraction of unreacted PDn in the samples may contribute to maintain 
this band. 
The bands at 1076 cm-1 and 993 cm-1 are mainly attributed to PO-O- 
and PO-OH,48 and they  changed after complexation with MnO. 
Indeed, peak shoulders were observed at 1045 cm-1 and 938 cm-1 
respectively. This is in accordance with previous results,40, 47, 49 and 
confirms the involvement of the phosphonate group in the chelation. 
However, the band at 993 cm-1 was not fully attenuated after 
complexation with MnO, suggesting that a certain fraction of 
unreacted phosphonate groups is still present after reaction with 
MnO. Because P=O and PO-O- bands appear changed after 
chelation, this is a strong evidence that the type of chelation is at 
least bidendate.50   
Whereas EDS (described in section 3.1), performed with an electron 
probe of a few nm2 only, allowed to confirm the strong presence of P 
at the outer surface of particles, XPS spectra were used to study the 
nature of the chemical binding occurring between the phosphonate 
groups and the MnO surface. XPS has a relatively large X-ray probe 
(the total area irradiated by the X-rays, ~1 mm2), therefore MnO-
oleate, bisphosphonate dendrons (PDn) and MnO@PDn samples 
were dispersed on flat substrates, then analysed by XPS to provide 
elemental information of about 5 – 10 nm in depth. XPS spectra 
survey results are presented in Table 1 and high resolution spectra of 
O (1s) and P (2p) in Figure 4. The O/C ratios of MnO-oleate 
particles (0.301) were higher than the theoretical O/C ratio (0.111) 
expected for oleate only. Because the analytical penetration depth of 
XPS is about 5 nm, the higher oxygen content was mainly attributed 
to MnO. High oxygen contents also reflect the thinness of the oleate 
coating (see Figure 1.d). After dendron grafting, the relative fraction 
of Mn strongly decreased, in agreement with the expected thicker 
dendrons coatings. The difference of thicknesses between dendron 
and oleate coatings is clearly illustrated in Figure 1.d and Figure 1.e. 
During the grafting process in water, a network of hydrogen bonds 
forms between the bisphosphonates and the carboxylates. This 
arrangement likely generates a bilayer of dendritic molecules. 
Increasing hydrodynamic diameters observed after 21 days in water, 
seem to corroborate this hypothesis. In 154 mM NaCl however, the 
strong concentration of Na2+ counter-ions impacts on the hydrogen 
bonds, as reflected by the decreasing hydrodynamic diameters 
(Figure 2.c). The presence of a broad band at 3600 - 3200 cm-1 in the 
MnO@PDn FTIR spectrum (Figure 2), absent from the PDn 
spectrum, also indicates the strong presence of hydrogen bonds.  
In XPS O (1s) high resolution spectra, the band at 531.5 eV was 
attributed to P=O, P-O-Mn, MnOH ; that at 532.9 – 533.2 eV to -C-
O- and to oxygen in –COOH, -CONH; the one at 534.0-534.5 eV to 
P-OH.51-53 The contribution at 531.5 eV strongly increased after 
dendron grafting on the MnO nanoparticles, mainly due to the 
contribution of P-O-Mn, MnOH (Table 1). The contribution at 534.5 
eV, associated to P-OH, decreased. This indicates the involvement of 
the P-O bond in the chelation.49, 51, 53 The involvement of 
phosphonate groups in the chelation process was also evidenced by 
the chemical shift of the P2p band, from 133.9 eV for the free 
dendron to 133.2 eV (0.7 eV shift) for PDn chelated on MnO 
nanoparticles (Figures 4.b and 4.d, respectively). This shift is 
consistent with previous results evidenced with dendronised iron 
oxide nanoparticles and its value larger than 0.5 confirms the 
deprotonation of both -P-OH terminations and thus the formation of 
at least two P−O−Fe bonds.47 Finally, due to its very low detection 
sensitivity, the Mn 3s peak could not be efficiently revealed. 
However, the main Mn2p peak was centred at 641.6 eV for the 
MnO@dendron, compared to 641.3 eV for MnO@oleate. This 
indicates that Mn2+ is the main oxidation state in both systems. 
3.3. Relaxometric analysis and in vitro MRI performance  
The relaxometric rates (1/T1, 1/T2) of MnO@PDn suspensions were 
calculated, and the results were plotted against the concentration of 
manganese (Figure 5). Longitudinal relaxivity values (r1 = 4.4 mM
-
1s-1) in the same order than for Gd-DTPA and Gd-DOTA were 
found, much higher than for PEG-lipid-coated MnO particles of 7 
nm core diameter reported in the literature (0.37 mM-1s-1 at 3T).8 
The dendron coating confers to MnO particles of 7 – 8 nm diam., 
relaxometric properties relatively similar to that demonstrated by 
dimercaptosuccinic acid-PEG and carboxymethyldextran coatings, 
which are efficient “positive” CAs for  T1-weighted MRI. Indeed, 
MnO particles of similar size (7-8 nm core diam.) coated with 
DMSA-PEG or carboxymethyldextran, have relaxometric ratios in 
the same order as MnO@PDns (r2/r1 ∼ 4; r1= 3.4 mM
-1s-1 for 
DMSA-PEG, and r2/r1 = 5.3; r1 = 5.4 mM
-1s-1 for 
carboxymethyldextran, both measured at 1.5 Tesla).11, 18 As a 
comparison, the expected relaxivities for Mn2+ ions measured at 1.41 
Tesla and 25oC are  r1 = 5.2 mM
-1s-1 and r2 = 61 mM
-1s-1.35 
Therefore, the relaxometric ratios measured for MnO@PDn are 
more favorable to  T1-weighted  imaging compared to  that of Mn
2+ 
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ions only (r2/r1∼ 10 at 1.41 T). Finally, the MnO@PDn suspensions 
imaged in MRI provided a clear positive contrast enhancement with 
an optimum value around 0.66 mM Mn (Figure 3).  
3.4. Dynamic contrast-enhanced MRI experiments 
Mice were injected with 100 µL of MnO@PDn (4.4 mM Mn, T1 = 
48 ms), which corresponds to a 24.2 µg-dose of Mn per 20 g-animal 
(0.44 µmol Mn/injection). The amount of injected Mn was kept in 
the same order as the indicated dosage for Mn-DPDP (Telascan), 5 – 
10 µmolMn/kg.54 Before administration of the CA, a T1-weighted 2-
D MRI spin echo scan was performed, and coronal images of the 
animals were acquired. Then, the animals were injected and a 
pronounced blood signal increase was observed, allowing for an 
excellent visualization of the abdominal vasculature (Figure 6). The 
mice were scanned in continuous during 120 minutes, then at time 
points (t = 8h, 24h, 48h). Up to 48 hours (end of the experiment), the 
animals did not show any sign of discomfort, and no apparent 
change was noted in their behaviour and feeding.  
Coronal images are represented in Figure 4 for slices corresponding 
to the gall bladder (a), kidneys (b) and urinary bladder (c). In these 
images, regions of interest (ROIs) were drawn over each of these 
organs, and the signal was integrated over each area. The results 
were plotted in the form of signal-enhancement graphs (Figure 7). 
Ultra-small MnO@PDn particles provided a clear and persistent 
vascular signal enhancement effect in the first 20 minutes following 
their injection, with a maximum at ∼ 10 minutes (Figure 7.a). 
Usually, no significant blood signal enhancement is observed in the 
first 5 minutes following i.v. injections of MnCl2 (free Mn
2+ ions).54 
Therefore, the persistence of vascular signal enhancement is clearly 
due to the presence of PEG-PDn-stabilised nanoparticles. Also, the 
measurement of nanoparticle vascular concentration is not as 
straightforward when using iron oxide nanoparticles. The “negative” 
contrast behaviour of dendron-coated iron oxide nanoparticles does 
not allow the correlation of signal change with nanoparticle 
concentration.38, 40 Therefore, the blood retention of PEG-dendron-
coated nanoparticles had never been measured until now. The 
present study demonstrates that vascular concentrations of PDn-
stabilised MnO-particles can be followed with MRI, which is a very 
strong advantage in the perspective of developing molecular imaging 
probes based on metal oxide nanoparticles.  In fact, this is the first 
study to provide a comprehensive in vivo monitoring and 
biodistribution profile of PEG-dendron-stabilised nanoparticles. 
The signal enhancement profiles of MnO@PDn in the liver suggest a 
biodistribution profile of Mn that is very different to what is 
typically observed for i.v. injected Mn2+ ions. In rats injected with 
100 µmol of MnCl2/kg of body weight, levels of Mn in the liver 
reached 38% of the total injected dose after 30 minutes. HSA-coated 
MnO particles of hydrodynamic diameter ∼ 39 nm, also showed a 
rapid and massive liver uptake after one hour only, which was 
attributed to sequestration by the RES.55 Such a dramatic influx of 
Mn in the liver was not observed in the present study (Figure S6). 
Then, after one (1) hour, a strong signal enhancement was observed 
in the gall bladder (full arrowhead, Figure 6), but not in the liver. 
This brilliance persisted over at least 8 hours (Figure 6 and 7.c). 
After 24 hours however, the Mn concentration in the gall bladder 
seemed attenuated. In the blood, Mn2+, whether free or bound to 
proteins, is efficiently cleared by the liver and any excess is normally 
excreted in the bile.36 MnO@PDn apparently follows the same 
elimination pathway, however not following the same kinetics.  
The excretion of Mn2+ also occurs through the gastrointestinal 
mucosa and pancreatic secretions. Virtually none is excreted through 
the kidneys.56-58 Evidences were found of strong urine elimination 
from the first minutes following MnO@PDn administration (Figure 
6). Urinary excretion is usually not observed after i.v. administration 
of MnCl2.
54 However, evidences of urinary excretion were recently 
reported for PDn-grafted iron oxide nanoparticles injected in mice.38, 
40 In the present study, because MnO@PDN particles are a 
“positive” contrast agent, the kinetics of nanoparticle kidney and 
urine transit were measured with MRI. Signal enhancement in the 
urine reached a peak value of 1.78 after 60 minutes (Figure 7.b). In 
the kidneys, signal enhancement was present in both the cortex and 
in the pyelon. This was confirmed by the comparison of signal 
enhancement profiles obtained for the kidneys (Figure 5.c) and for 
the urinary bladder (Figure 7.d). Therefore, it can be concluded that 
grafting PDns at the surface of ultra-small particles is a promising 
strategy to enhance the excretion of molecular imaging probes, 
which is particularly critical when potentially toxic ions (such as 
Mn2+) could be involved. Finally, no evidence was found of contrast 
enhancement in the brain (data not shown). 
3.5. Manganese biodistribution study 
After DCE-MRI studies, the levels of manganese in organs were 
measured at t = 24h and t = 48h, using neutron activation analysis. In 
fact, this is the first study that provides a comprehensive 
biodistribution study of ultra-small MnO nanoparticles. Until now, 
there had been no organ biodistribution performed with i.v.-injected 
MnO nanoparticles, and few data has been reported on the transit of 
these particles through the urinary, gastro-intestinal or hepatobiliairy 
pathways.  
The total amount of Mn injected in animals corresponds to 1.21 mg 
Mn/kg of body weight (22 µmol Mn/kg). As shown in Table 2, very 
low manganese levels were found in the blood after 24 hours, which 
is consistent with the DCE-MRI results. The highest concentrations 
of Mn were found in the feces, intestine, gall bladder, kidneys and 
stomach, in decreasing order of contents. In spite of the high 
endogenous presence of Mn expected in the liver and in the spleen, 
limited concentrations of Mn were found in these organs, as well as 
in the lungs. In fact, the tissues rich in mitochondria – such as liver, 
kidney, heart, and pancreas, contain the highest levels of endogenous 
manganese.59, 60 The low Mn contents in the liver confirm that RES 
sequestration is not the preponderant nanoparticle elimination 
pathway of MnO@PDn. 
Recently, Huang, Chen et al investigated with MRI and PET, the 
tumour contrast enhancement potential of albumin-coated MnO 
particles (r1 = 1.97 mM
-1s-1; dH = 39.2 ± 3.6 nm). Massive uptake by 
the liver was evidenced in the PET data, as soon as one hour after 
injection.55 These results indicated that MnO particles, as many other 
inorganic core nanoparticles in that size range, are strongly 
sequestrated by the RES if they are not adequately coated with 
molecules preventing or delaying their opsonisation. RES-
sequestrated nanoparticles are more susceptible to remain in the 
organism for longer periods, which in the case of Mn2+-containing 
nanoparticles, would represent a toxicological risk. 
On the contrary, MnO@PDn nanoparticles are not significatively 
uptaken in the liver. Therefore, grafting PDns at the surface of 
nanoparticles enhance their biocompatibility profile, and makes them 
applicable to biomedical procedures. Based on Mn concentration 
measurements in organs, we calculated the rate of Mn decrease 
between 24h and 48h. The strongest Mn elimination values were 
found for the following organs:  bladder, heart, liver, kidneys, gall 
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bladder and lungs. At 48h, very strong concentrations of Mn were 
found in the feces, intestine, as well as in the stomach (possible 
contamination at the extraction, during separation from the 
gastrointestinal tract). All results converge to hepatobiliairy 
elimination as the main pathway for the clearance of MnO@PDns.   
Then, we calculated the retention of MnO@PDn in the heart, lungs, 
liver, gall bladder, kidneys, spleen and in the bladder, and expressed 
it units of % of injected dose (% I.D., Table 3). For this, the 
endogenous amounts of Mn in mice organs, well documented in the 
literature (summarised in the supporting info, Table S1), were 
subtracted from the neutron activation analysis data obtained for 
each organ. The endogenous Mn concentrations reported in the 
literature are as follows: of 0.18 – 0.4 µg Mn/g for the heart, 0.18 µg 
Mn/g for the lungs, 1- 2.1 µg Mn/g for the liver, 0.94 – 1.6 µg Mn/g 
for the kidneys, and 0.4 – 0.45 µg Mn/g for the spleen.61-63 The 
levels of Mn in the intestine, feces, and stomach are highly 
dependent on the diet of animals and therefore these values are 
variable. As an indication, Damadian et al found Mn levels of 4.27 
µg Mn/g for the stomach, and 3.36 µg Mn/g for the gastro-intestinal 
tracts.61 Because of the usually high and variable endogenous Mn 
contents in stomach and in the gastro-intestinal tract, we did not 
include these organs in the final calculation of MnO@PDn organ 
retention.  
After 24 hours, the strongest fractions of MnO@PDn were found in 
the gallbladder (25.7%), in the kidneys (21%), in the liver (14.8%), 
and in the heart (7.9%). After 48 hours, these data had decreased to 
11%, 8.3%, 5.7%, and 3.0%, respectively.  By comparison, rats 
injected with 100 µmol of MnCl2/kg of body weight showed a total 
Mn retention of 50% after 7 days. In the present study, for the 
interval included between 24h and 48h, and considering only the 
group of seven (7) organs mentioned in Table 3, the total % I.D. 
decrease was 42.7%. Indeed, the body clearance of MnO@PDns 
particles through the hepatobiliairy pathway occurs much faster than 
for MnCl2, with a % of total I.D. retention estimated to 31% after 
48h. The very low amount of Mn found in the spleen, further 
confirms that PDn-pegylated MnO nanoparticles are not taken up by 
the RES, and could therefore be considered as advantageous probes 
for molecular MR imaging. 
4 Conclusions  
Ultra-small MnO particles were pegylated with small, biocompatible 
and highly hydrophilic bis-phosphonate dendrons (PDns). The new 
MnO colloids are very stable, and they induce “positive” MRI 
contrast enhancement potentially advantageous in molecular imaging 
procedures. In this study, we demonstrated that PDn-grafted ultra-
small MnO nanoparticles are eliminated through the hepatobiliairy 
pathway, and this considerably mitigates the risk that represents the 
potential sequestration of MnO particles by the reticuliendothelial 
system. Evidences of urinary excretion were also found. 
Applications of MnO nanoparticles as imaging probes in medicine 
have always appeared hindered by their potential toxicity. The 
present study confirms that MnO nanoparticles adequately coated 
with stabilizing molecules favouring their efficient and rapid 
elimination through faeces and urine, could find promising uses as 
“positive” MRI CAs. Finally, PDn grafting could advantageously be 
applied to other metal oxide nanoparticles of potential interest in 
medicine, and in particular on the development of multi-modality 
tracers for molecular imaging (e.g. with radioactive, fluorescent and 
bioactive functionalities).  
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Table 1.  XPS analyses of Mn, O, N, C and P elements at the surface of 
MnO@PDn. 
 
Sample Mn2p O1s N1s C1s P2p O/C P/N 
MnO@oleate
4.6 
 
 
 
20.4 
(5.5% Mn-O) 
 
[13.8% C-O] 
{1.1% COOH} 
- 
 
 
 
67.7 
(63.8% C-C / 
CH) 
[1.8% C-O] 
{2.1% C=O} 
- 
 
 
 
0.301 
 
 
 
- 
 
 
 
MnO@PDn 
0.9 
 
 
 
 
 
33.9 
(8.1% P=O / 
Mn-O-P / 
Mn-OH) 
[24.6% C-O] 
{1.2% P-OH} 
0.9 
 
 
 
 
60.1 
(18.2% C-C / 
CH) 
 
[37.5% C-O] 
{4.3% C=O} 
2.1 
 
 
 
 
0.564 
 
 
 
 
2.333 
 
 
 
 
Dendron 
(PDn) 
- 
 
 
27.4 
(2.3% P=O) 
 
[22.1% C-O] 
{3.0% C=O} 
1.1 
 
 
67.3 
(35.6% C-C / 
CH) 
[24.8% C-O] 
{3.3% C=O} 
1.3 
 
 
0.407 
 
 
1.182 
 
 
***The balance in XPS for MnO@oleate, MnO@dendron, and dendron were 
Si, Na and Cl. 
 
 
 
 
 
Table 2. Manganese levels in organs after 24 and 48h following injections of 
MnO@PDns (0.44 µmol Mn/animal) 
 
 Organs 
24 h 
± std. 
dev 
48h 
± std. 
dev 
% 
change 
  
µg Mn / g 
organ  
µg Mn / g 
organ   
1 blood 0.06 0.04 0.04 0.03 -28 
2 heart 2.2 0.1 0.80 0.06 -175 
3 lungs 0.84* 0.03* 0.35 0.10 -139 
4 liver 3.9 0.3 1.46 0.04 -165 
5 gallbladder 6.50* 0.03* 2.8* 1.0* -130 
6 stomach 4 2 13 9 70 
7 kidneys 5.3 0.6 2.09 0.05 -156 
8 
bladder + 
urine 0.6 0.2 0.11 0.01 -405 
9 intestine 32 10 24 4 -31 
10 spleen 0.46 0.04 0.34* 0.02* -37 
11 feces 149 56 114 24 -31 
12 pancreas 6 2 3.0 0.4 -86 
All measurements performed in triplicate except for * (2 measures) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Retention of MnO@PDn in organs, in % of injected dose (I.D.) of 
MnO@PDs (0.44 µmol Mn/animal) at t = 0. Except for gall bladder and 
bladder, the expected endogenous Mn levels were subtracted from the 
measured Mn values to calculate % I.D. 
 
Organs 24 h 48 h 
% 
change 
 % I.D. ± % I.D. ±  
heart 7.9% 0.3% 3.0% 0.2% -62 
lungs 2.3% 0.1% 1.1% 0.3% -50 
liver 14.8% 1.3% 5.7% 0.1% -61 
gallbladder 25.7% 0.1% 11% 4% -56 
kidneys 21% 2% 8.3% 0.2% -60 
bladder + 
urine 
1.1% 0.3% 0.14% 0.02% -88 
spleen 0.70% 0.07% 1.06% 0.05% 52 
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Figure 1. a) Schematic representation of the bisphosphonate dendron synthesis and grafting procedure. 
Oleate molecules initially coating the MnO nanocrystals (b), are efficiently removed from the surface and 
replaced by bisphosphonate dendrons (c). TEM images of MnO particles before (d) and after (e) PDn 
grafting. 
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 Figure 2. a) HRTEM images of MnO@PDn particles with evidences of crystallographic lattices (white arrow). b) A 
moderate number of small MnO@PDn agglomerates were found, as well as evidences of the limited presence of 
unreacted PDn (dashed white arrow). Hydrodynamic diameter measurements in water and in 154 mM NaCl  c) in 
intensity, d) in volume and e) in number 
 
Figure 3. a) FTIR spectra of MnO@oleate and MnO@PDn particles; b) close-up on the phosphonate peaks area for the 
free dendron and the grafted MnO@PDn particles. 
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Figure 4. O1s and P2p high resolution spectra of dendron (a, b) and MnO@dendron (c,d) 
 
Figure 5. Relaxivity curves (a) and contrast enhancement in T1-w. MRI (TE/TR: 11/400 ms) for MnO@PDn solutions 
in 154mM NaCl. 
 
Figure 6. MRI images of MnO@PDn-injected mice at t = 0, 10 min, 1, 8, 24 and 48h, for a) the gall bladder, b) the 
kidneys, c) the urinary bladder. The full arrowhead points to the gall bladder; the full arrow points to the abdominal 
aorta; the empty arrow points to the kidneys; the empty arrowhead points to urinary bladder.  
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 Figure 7. MRI signal (SI) follow-up studies after injection of MnO@PDn, for a) blood (abdominal vessels), b) gall 
bladder, c) kidneys and d) bladder. Each point represents the average of at least three measurements performed in three 
mice. The data were pooled in 10-min. time intervals, and horizontal error bars indicate the extremes of each interval.  
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Ultra-small MnO nanoparticles pegylated with bis-
phosphonate dendrons are efficient positive contrast 
agents in T1-w. MRI. Intravenous injections of 
MnO@PDn provide prolonged vascular signal 
enhancement in MRI, followed by efficient excretion 
through the hepatobiliairy and urinary ways. The 
potential toxicity of MnO nanoparticles is thereby 
considerably decreased, and could allow their use as 
biomedical MR probes. 
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